TARRYTOWN, N.Y., Feb. 8 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. today announced that it will present at the BIO CEO & Investor Conference, taking place on February 12-14, 2007 at the Waldorf- Astoria Hotel in New York City. Lewis H. Bender, President and Chief Executive Officer, will present on Wednesday, February 14 at 12:00 p.m. ET.
A live audio webcast of Emisphere’s presentation will be available on the Investor Relations section of the Company’s web site at http://www.emisphere.com/ir.asp or directly at: http://www.corporate- ir.net/ireye/conflobby.zhtml?ticker=EMIS&item_id=1450947
Please visit the website at least five minutes prior to start time for instructions. A replay of the presentation will be available on the Investor Relations portion of Emisphere’s website approximately one hour after the presentation through March 14, 2007.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering the oral delivery of otherwise injectable drugs. Emisphere’s business strategy is to develop oral forms of injectable drugs, either alone or with corporate partners, by applying its proprietary eligen(R) technology to those drugs or licensing its eligen(R) technology to partners who typically apply it directly to their marketed drugs. Emisphere’s eligen(R) technology has enabled the oral delivery of proteins, peptides, macromolecules and charged organics. Emisphere and its partners have advanced oral formulations or prototypes of salmon calcitonin, heparin, insulin, parathyroid hormone, human growth hormone and cromolyn sodium into clinical trials. Emisphere has strategic alliances with world-leading pharmaceutical companies. For further information, please visit the Emisphere website, http://www.emisphere.com .
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere’s product candidates and the sufficiency of Emisphere’s cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere’s drug delivery technology, Emisphere’s ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere’s filings with the Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in Emisphere’s Annual Report on Form 10-K (file no. 1-10615) filed on March 16, 2006, and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2006, June 30, 2006, and September 30, 2006.
Emisphere Technologies, Inc.
CONTACT: Stewart Siskind, Investor Relations, Emisphere Technologies,Inc., +1-914-785-4742; or Dan Budwick, BMC Communications, +1-212-477-9007ext. 14
Web site: http://www.emisphere.com/
